@article{discovery10064487,
            year = {2018},
         journal = {Parkinsonism \& Related Disorders},
           month = {November},
          volume = {56},
           title = {Serum neurofilament light chain in progressive supranuclear palsy},
            note = {This version is the author accepted manuscript. For information on re-use, please refer to the publisher's terms and conditions.},
           pages = {98--101},
          author = {Donker Kaat, L and Meeter, LH and Chiu, WZ and Melhem, S and Boon, AJW and Blennow, K and Zetterberg, H and van Swieten, JC},
        abstract = {INTRODUCTION: Neurofilament light chain (NfL) is a promising biomarker in neurodegenerative diseases. Elevated NfL levels in CSF and blood have been observed in a growing number of neurodegenerative disorders, including frontotemporal dementia and Alzheimer's disease. We studied serum NfL levels in patients with progressive supranuclear palsy (PSP) in relation to disease severity and survival. METHODS: Serum NfL levels were determined cross-sectionally in a retrospective cohort of 131 patients with PSP and 95 healthy controls. Detailed clinical examination was performed and disease severity was assessed by several rating scales. RESULTS: We found that serum NfL levels in PSP were twice as high as those in controls, and that NfL levels correlated with worse functional, motor and cognitive functioning. During follow-up, 119 PSP patients had died, and higher NfL levels were associated with a shorter survival. CONCLUSION: This study provides evidence that serum NfL is a relevant and promising biomarker in PSP for disease severity, and may be used as a prognostic tool to predict survival in clinical practice.},
        keywords = {Biomarker, Neurofilament, Progressive supranuclear palsy},
            issn = {1353-8020},
             url = {https://doi.org/10.1016/j.parkreldis.2018.06.018}
}